TCGA-CQ-5323-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V2+0.400
- MITOTIC_SPINDLE+0.390
- INTERFERON_ALPHA_RESPONSE+0.330
- SPERMATOGENESIS+0.320
- APICAL_SURFACE+0.220
- INTERFERON_GAMMA_RESPONSE+0.220
- HEDGEHOG_SIGNALING+0.210
- MYC_TARGETS_V1+0.180
Top 10 suppressed
- ANGIOGENESIS-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- COAGULATION-0.370
- MYOGENESIS-0.260
- PROTEIN_SECRETION-0.260
- COMPLEMENT-0.200
- HYPOXIA-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- BILE_ACID_METABOLISM-0.180
- OXIDATIVE_PHOSPHORYLATION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 83a1d91a-3e74-4106-96d1-eec558404c29 | — | — | 0.754 |
| 2 | C3N-04162 | — | cohortSQ2 | 0.741 |
| 3 | TCGA-RS-A6TP-01A-12R-A34R-07 | — | — | 0.729 |
| 4 | TCGA-HL-7533-01A-11R-2232-07 | — | — | 0.720 |
| 5 | TCGA-AO-A124-01A-11R-A10J-07 | — | E | 0.719 |
| 6 | TCGA-BT-A20V-01A-11R-A14Y-07 | — | — | 0.715 |
| 7 | 19-001pA3-U | — | — | 0.707 |
| 8 | 431EAB8C-D0B4-4440-A2B6-1D001B0026E2 | — | — | 0.702 |
| 9 | TCGA-BH-A0DD-01A-31R-A12P-07 | — | B | 0.700 |
| 10 | TCGA-CX-7086-01A-11R-2081-07 | — | — | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |